Limin Shang

Leadership Team

Limin Shang, Director of Pharmacology

After obtaining a PhD in pharmacology from SUNY Buffalo State, Buffalo, NY, Limin worked on animal disease models for several years at the Roswell Park Cancer Institute and Mount Sinai School of Medicine, NY.

At Novimmune since 2009, he was involved in the preclinical development of several therapeutic antibody programs in autoimmunity and κλ body bispecific antibody programs in immuno-oncology.

Back

First patient dosed with NILK-2301 in Phase I clinical trial

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer


Read more

LinkedIn